Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for nanotechnology industry professionals · Friday, March 29, 2024 · 699,686,611 Articles · 3+ Million Readers

Chronic Rhinosinusitis Market to Hits USD 3508.0 Million by 2027 by Size, Share, Growth and Top Players Analysis

Emergen Research Logo

Emergen Research Logo

Adoption of minimally invasive techniques, technological advancements, substantial prevalence of rhinosinusitis with favorable reimbursement scenarios

Market Size – USD 2132.5 Million in 2019, Market Growth – CAGR of 7.4%, Market Trends– growing prevalence of chronic asthma, potential investment opportunities, and technological advancements”
— Emergen Research

VANCOUVER, BC, CANADA, September 23, 2022 /EINPresswire.com/ -- The global Chronic Rhinosinusitis Market was valued at USD 2132.5 million in 2019 and is expected to reach USD 3508.0 million by 2027, at a CAGR of 7.4%, According to the current analysis of Emergen Research. Development and manufacture of proficient sinusitis drugs are likely to be highly demanded for efficient treatment of chronic rhinosinusitis as, pollutants, fungal infections and allergies immensely contribute to the rising incidence of rhinosinusitis.

Moreover, growing prevalence of growing prevalence of chronic asthma, inflammation of mucosal linings of the nasal passage, and cases of paranasal sinuses are expected to fuel the growth prospects of chronic rhinosinusitis market in the forecast period. Roughly more than 15 million people suffer from chronic symptoms of rhinosinusitis in the United States, that is, prevalence of chronic rhinosinusitis ranges from 1% to 5% of the total US population.

Get a sample of the report @ https://www.emergenresearch.com/request-sample/74

Chronic rhinosinusitis is primarily characterized by nasel blockage, inflammation of the sinus and nasel linings, facial pain along with rhinorrhea and loss of sense of smell. Effective treatment includes improvement in sinus outflow, enhancement of mucociliary clearance and elimination of inflammation and local infection among other associated treatments.

Additionally, increase in implementation of minimally invasive surgical procedures, widespread awareness concerning the symptoms of the target disease across regions and technological progressions among other favorable scenarios are likely to augment the growth of industry during the period of 2020-2027.

Competitive Outlook:

The global Chronic Rhinosinusitis market is highly consolidated due to the presence of a large number of companies across this industry. These companies are known to make hefty investments in research and development projects. Also, they control a considerable portion of the overall market share, thus limiting the entry of new players into the sector.  The global Chronic Rhinosinusitis market report studies the prudent tactics undertaken by the leading market players, such as partnerships and collaborations, mergers & acquisitions, new product launches, and joint ventures.

Some major companies in the global market report include AstraZeneca, Bayer AG, Ivax Pharmaceuticals, Pfizer, Novartis Pharmaceuticals Corporation, Sanofi, Sunovion Pharmaceuticals, Cipla, Smith & Nephew, Medtronic, SinuSys Corporation, Olympus Corporation and Acclarent among other companies

Request a discount on the report @ https://www.emergenresearch.com/request-discount/74

Some Key Highlights from the Report

Xolair (Omalizumab) manufactured by Novartis, was approved in August 2020, by European Commission (EC). The product development is attributed to treat severe chronic rhinosinusitis with nasal polyps

Due to considerable employability of antibiotics and their effectiveness in efficiently treating chronic rhinosinusitis, antibiotics product segment held largest market share of 41.6% in 2019 and is likely to dominate the industry during 2019-2027

Immune deficiency disease segment in the disease outlook registered highest CAGR of 7.1% in 2019 whereas, anatomical differences disease segment accounted for largest market share of approximately 37.5% owing to increase in prevalence of target disease across the globe

Regeneron Pharmaceuticals and Sanofi’s Dupixent (Dupilumab) was approved in June 2019, by US Food and Drug Administration (FDA). This drug is customized for adults with incompetently controlled chronic rhinosinusitis along with nasal polyposis

Emergen Research have segmented Chronic Rhinosinusitis Market on the basis of product, disease type, distribution channel and region:

Product Outlook (Revenue in Million USD; 2017–2027)

Steroids

Topical Nasal Steroid

Systemic Steroids

Nasal Irrigation

Hypertonic and Isotonic Saline

Steroid Nasal Irrigation

Topical Antibiotic Therapy

Surgical Based

Ethmoidectomy

Endoscopic Intranasal Intervention

Others

Antibiotics

Amoxicillin-Clavulanate

Clindamycin

Sulfamethoxazole

Levofloxacin

Macrolide Therapy

Antifungal Therapy

Disease Outlook (Revenue in Million USD; 2017–2027)

Anatomical Differences

Nasal Tumors

Mucosal Edema

Non-Allergic Rhinitis

Immune Deficiency

Other

Distribution Channel (Revenue in Million USD; 2017–2027)

Hospital Pharmacies

Retail Pharmacies

Drug Stores

Other

To know more about the report @ https://www.emergenresearch.com/industry-report/chronic-rhinosinusitis-market

Global Chronic Rhinosinusitis Market Geographical Landscape - Synopsis:

The report closely studies the growth trajectory of the global Chronic Rhinosinusitis market. It brings to light the global dominance of the leading regional segments, including North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

The study elaborates on the crucial information pertaining to the regional market share. It simultaneously focuses on the significant details about the growth patterns of each regional market.

Moreover, the report encases an exhaustive geographical study of the market, emphasizing the business growth prospects and market barriers for each of the key market regions.

Key Benefits of Buying the Global Chronic Rhinosinusitis Report:

Comprehensive analysis of the changing competitive landscape

Assists in decision making processes for the businesses along with detailed strategic planning methodologies

The report offers an 8-year forecast and assessment of the Global Chronic Rhinosinusitis Market

Helps in understanding the key product segments and their estimated growth rate

In-depth analysis of market drivers, restraints, trends, and opportunities

Comprehensive regional analysis of the Global Chronic Rhinosinusitis Market

Extensive profiling of the key stakeholders of the business sphere

Detailed analysis of the factors influencing the growth of the Global Chronic Rhinosinusitis Market

Request a customization of the report @ https://www.emergenresearch.com/request-for-customization/74

Thank you for reading the research report. To get more information about the customized report and customization plan, kindly connect to us and we will provide you with the well-suited customized report.

Take a Look at our other Reports:

Dental 3D Printing Market

https://www.biospace.com/article/dental-3d-printing-market-size-to-reach-valuation-of-usd-12-46-billion-in-2028-growing-at-a-cagr-of-26-5-percent-according-to-latest-analysis-by-emergen-research/

Hemodynamic Monitoring Devices Market

https://www.biospace.com/article/hemodynamic-monitoring-devices-market-size-to-reach-valuation-of-usd-1-566-7-million-in-2028-growing-at-a-cagr-of-6-1-percent-according-to-latest-analysis-by-emergen-research-/

Near Infrared Spectroscopy Market

https://www.biospace.com/article/near-infrared-spectroscopy-market-size-to-reach-valuation-of-usd-437-3-million-in-2028-growing-at-a-cagr-of-6-2-percent-according-to-emergen-research/

Nerve Repair and Regeneration Market

https://www.biospace.com/article/nerve-repair-and-regeneration-market-size-to-reach-valuation-of-usd-11-62-billion-by-2027-growing-at-a-cagr-of-9-0-percent-according-to-emergen-research/

Reproductive Genetics Market

https://www.biospace.com/article/reproductive-genetics-market-size-to-reach-valuation-of-usd-11-23-billion-in-2028-growing-at-a-cagr-of-12-3-percent-according-to-latest-analysis-by-emergen-research/

About Us:

At Emergen Research, we believe in advancing with technology. We are growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Read Full Press Release @ https://www.emergenresearch.com/press-release/global-chronic-rhinosinusitis-market

Eric Lee
Emergen Research
+91 90210 91709
sales@emergenresearch.com
Visit us on social media:
Facebook
Twitter
LinkedIn

Powered by EIN Presswire
Distribution channels: Healthcare & Pharmaceuticals Industry


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release